Zacks Research Raises Earnings Estimates for Editas Medicine

Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Equities research analysts at Zacks Research increased their Q2 2025 EPS estimates for Editas Medicine in a research note issued to investors on Monday, June 2nd. Zacks Research analyst A. Chakraborty now anticipates that the company will post earnings per share of ($0.46) for the quarter, up from their previous estimate of ($0.66). The consensus estimate for Editas Medicine's current full-year earnings is ($2.71) per share. Zacks Research also issued estimates for Editas Medicine's Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.69) EPS, Q1 2026 earnings at ($0.47) EPS, Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($1.87) EPS, Q1 2027 earnings at ($0.48) EPS and FY2027 earnings at ($1.85) EPS.

EDIT has been the topic of several other research reports. Cantor Fitzgerald upgraded shares of Editas Medicine from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 29th. Wall Street Zen upgraded shares of Editas Medicine from a "sell" rating to a "hold" rating in a research note on Wednesday, May 14th. Robert W. Baird dropped their price target on shares of Editas Medicine from $8.00 to $4.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 13th. Finally, HC Wainwright assumed coverage on shares of Editas Medicine in a research note on Monday, April 28th. They set a "buy" rating and a $3.00 price target on the stock. Two research analysts have rated the stock with a sell rating, nine have given a hold rating, two have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $5.36.

Editas Medicine Stock Performance

Shares of Editas Medicine stock traded up $0.11 on Wednesday, hitting $1.91. 2,450,899 shares of the company's stock were exchanged, compared to its average volume of 2,575,143. The company has a 50-day simple moving average of $1.46 and a 200-day simple moving average of $1.52. The stock has a market capitalization of $159.89 million, a PE ratio of -0.75 and a beta of 2.10. Editas Medicine has a 1 year low of $0.91 and a 1 year high of $6.22.

Editas Medicine (NASDAQ:EDIT - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.08. The business had revenue of $4.66 million for the quarter, compared to analysts' expectations of $0.79 million. Editas Medicine had a negative net margin of 340.96% and a negative return on equity of 80.13%. During the same quarter last year, the company posted ($76.00) EPS.

Insider Buying and Selling at Editas Medicine

In other Editas Medicine news, CEO Gilmore Neil O'neill sold 15,192 shares of Editas Medicine stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $1.72, for a total value of $26,130.24. Following the sale, the chief executive officer now directly owns 280,282 shares in the company, valued at approximately $482,085.04. The trade was a 5.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last ninety days, insiders have sold 16,364 shares of company stock worth $28,146. Insiders own 2.10% of the company's stock.

Institutional Trading of Editas Medicine

A number of institutional investors and hedge funds have recently bought and sold shares of EDIT. SG Americas Securities LLC increased its holdings in shares of Editas Medicine by 103.7% in the 4th quarter. SG Americas Securities LLC now owns 81,669 shares of the company's stock worth $104,000 after buying an additional 41,573 shares during the last quarter. Ieq Capital LLC bought a new stake in shares of Editas Medicine in the 4th quarter worth about $31,000. Raymond James Financial Inc. bought a new stake in shares of Editas Medicine in the 4th quarter worth about $303,000. Monaco Asset Management SAM bought a new stake in shares of Editas Medicine in the 4th quarter worth about $1,359,000. Finally, Intech Investment Management LLC increased its holdings in shares of Editas Medicine by 43.1% in the 4th quarter. Intech Investment Management LLC now owns 40,942 shares of the company's stock worth $52,000 after buying an additional 12,336 shares during the last quarter. 71.90% of the stock is currently owned by institutional investors.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.